1190861-43-8

Basic information

• Product Name: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE
• Synonyms: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE;6-bromospiro[1H-indole-3,4'-oxane]-2-one;6-Bromo-1H-spiro[indole-3,4'-oxane]-2-one
• CAS NO: 1190861-43-8
• Molecular Formula: C₁₂H₁₂BrNO₂
• Molecular Weight: 282.13318
• Mol File: 1190861-43-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 437.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.61±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.70±0.20(Predicted)
• CAS DataBase Reference: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE(1190861-43-8)
• EPA Substance Registry System: 6-BROMO-2',3',5',6'-TETRAHYDROSPIRO[INDOLINE-3,4'-PYRAN]-2-ONE(1190861-43-8)

Safety Data

• Hazardous Substances Data: 1190861-43-8(Hazardous Substances Data)

Usage

Description

6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is a chemical compound characterized by its unique spirocyclic structure, which incorporates a bromine atom and a pyran ring. 6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is recognized for its potential as a building block in the synthesis of pharmaceuticals and bioactive compounds due to its distinctive structural features.

Uses

Used in Pharmaceutical Synthesis:
6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is utilized as a key intermediate in the development of various pharmaceuticals and bioactive compounds. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications.
Used in Antifungal Applications:
In the field of antifungal agents, 6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is employed for its potential to combat fungal infections, providing a new avenue for the treatment of various fungal diseases.
Used in Antibacterial Applications:
6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one also serves as an antibacterial agent, contributing to the development of new antibiotics to address the growing concern of antibiotic resistance.
Used in Anticancer Applications:
6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is being studied for its potential as an anticancer agent, with ongoing research exploring its ability to target and inhibit the growth of cancer cells.
Used in Neurological Disorder Treatment:
6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is being investigated for its potential use in the treatment of neurological disorders, suggesting a possible role in managing or alleviating symptoms associated with such conditions.
Used as an Anti-Inflammatory Agent:
6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one is also being explored for its anti-inflammatory properties, indicating a potential application in reducing inflammation and associated symptoms in various conditions.
Further research is necessary to fully understand and harness the potential applications of 6-Bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one in drug development and medicinal chemistry.

Upstream product

• 1190861-47-2 tert-butyl 6-bromo-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-1-carboxylate 
• 1202765-53-4 methyl 4-(4-bromo-2-nitrophenyl)tetrahydro-2H-pyran-4-carboxylate 
• 34270-90-1 2,2'-diiodoethyl ether 
• 99365-40-9 6-bromo-2,3-dihydro-1H-indole-2-one 
• 100487-82-9 4-bromo-2-nitro-benzoic acid methyl ester 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 100487-81-8 2-(4-bromo-2-nitro-phenyl)malonic acid dimethyl ester 

Downstream Products

• 1202765-56-7 6-bromo-2',3',5',6'-tetrahydrospiro[dihydroindole-3,4'-pyran] 
• 1190859-96-1 N-Cyclopropyl-4-methyl-3-(2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-6-yl)benzamide 
• 1190859-98-3 N-Isoxazol-3-yl-4-methyl-3-(2-oxo-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-pyran]-6-yl)benzamide 
• 1259513-65-9 1-(3-methyl-2-phenyl-4-quinolinyl)-6-(4-morpholinyl)-1,2,2',3',5',6'-hexahydrospiro[indole-3,4'-pyran] 

Relevant articles and documents

Preparation Method for Amide Compounds and Use Thereof in Medical Field

Provided are a preparation method for amide compounds and use thereof in medical field. Specifically, provided are small molecule amide compounds. Such compounds are inhibitors of enhancer homolog 2 (EZH2) of Zeste gene, and can be used for preventing and/or treating related diseases mediated by EZH2, including tumors, myeloproliferative diseases or autoimmune diseases.

Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors

Structure-based rational design led to the synthesis of a novel series of potent PI3K inhibitors. The optimized pyrrolopyridine analogue 63 was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochemical properties and pharmacokinetic profile for animal studies. Analogue 63 was found to be efficacious in animal models of inflammation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) disease model of rheumatoid arthritis. These studies highlight the potential therapeutic value of inhibiting both the PI3Kβ and δ isoforms in the treatment of a number of inflammatory diseases.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.